HIGHLIGHTS
- who: Glioma and collaborators from the Department of Neurosurgery, Harbin Medical University Cancer Hospital, Harbin, China, Department of Esophageal Surgery have published the research: Developing an Immune-Related Signature for Predicting Survival Rate and the Response to Immune Checkpoint Inhibitors in Patients With Glioma, in the Journal: (JOURNAL)
- what: Of this study demonstrated that the signature may aid in improved prognosis prediction, and may provide a novel theoretical basis for further elucidating immunotherapy options for glioma. Subsequently, results of this study demonstrated that a total of 118 DEIRGs were associated with the OS of patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.